Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-171M | $-155M | $-142M | -23.9% | - | -13.0% |
| 2024 | $0M | $-192M | $-178M | $-166M | -93.0% | - | 147.3% |
| 2023 | $0M | $-85M | $-72M | $-81M | -29.8% | - | 141.3% |
| 2022 | $0M | $-31M | $-30M | $-29M | 57.0% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 170.60 |
| Research And Development | 132.01 |
| Selling General And Administration | 38.60 |
| Total Expenses | 170.60 |
| Operating Income | -170.60 |
| Total Operating Income As Reported | -170.60 |
| EBITDA | -170.54 |
| Normalized EBITDA | -170.54 |
| EBIT | -170.60 |
| Interest Income | 15.95 |
| Interest Expense | - |
| Net Interest Income | 15.95 |
| Other Non Operating Income Expenses | - |
| Other Income Expense | - |
| Interest Income Non Operating | 15.95 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 15.95 |
| Pretax Income | -154.65 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -154.65 |
| Net Income From Continuing And Discontinued Operation | -154.65 |
| Net Income From Continuing Operation Net Minority Interest | -154.65 |
| Net Income | -154.65 |
| Net Income Common Stockholders | -154.65 |
| Net Income Including Noncontrolling Interests | -154.65 |
| Normalized Income | -154.65 |
| Diluted NI Availto Com Stockholders | -154.65 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 0.06 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Gain On Sale Of Security | - |
| General And Administrative Expense | 38.60 |
| Other Gand A | 38.60 |
| Otherunder Preferred Stock Dividend | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc.this co. | MLYS | $2.2B | -14.28 | 3.41 | -23.9% | - |
| Axogen, Inc. | AXGN | $2.3B | - | 17.49 | -12.2% | 4471.19 |
| Immunome, Inc. | IMNM | $2.2B | -10.49 | 3.51 | -33.5% | -7.14 |
| Enliven Therapeutics, Inc. | ELVN | $2.2B | -20.85 | 4.70 | -22.6% | -17.28 |
| BioCryst Pharmaceuticals, Inc. | BCRX |
| - |
| - |
| - |
| - |
| - |
| $2.2B |
| 8.16 |
| -18.07 |
| -221.4% |
| 7.20 |
| Kodiak Sciences Inc. | KOD | $2.1B | - | 13.58 | -146.1% | - |
| Aurinia Pharmaceuticals Inc. | AUPH | $2.1B | 7.33 | 3.62 | 49.4% | 15.22 |
| Clover Health Investments, Corp. | CLOV | $2.1B | -24.56 | 6.81 | -27.7% | - |
| NovoCure Limited | NVCR | $2.1B | - | 6.12 | -40.0% | - |
| Peer Median | - | -10.49 | 5.41 | -30.6% | 7.20 | |